14 research outputs found

    Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis

    No full text
    International audienceOBJECTIVES:To evaluate the incidence of anti-drug antibody (ADA) occurrences and ADA-related risk factors under adalimumab and infliximab treatment in rheumatoid arthritis (RA) patients.METHODS:The study combined retrospective cohorts from the ABIRISK project totaling 366 RA patients treated with adalimumab (n = 240) or infliximab (n = 126), 92.4% of them anti-TNF naive (n = 328/355) and 96.6% of them co-treated with methotrexate (n = 341/353) with up to 18 months follow-up. ADA positivity was measured by enzyme-linked immunosorbent assay. The cumulative incidence of ADA was estimated, and potential bio-clinical factors were investigated using a Cox regression model on interval-censored data.RESULTS:ADAs were detected within 18 months in 19.2% (n = 46) of the adalimumab-treated patients and 29.4% (n = 37) of the infliximab-treated patients. The cumulative incidence of ADA increased over time. In the adalimumab and infliximab groups, respectively, the incidence was 15.4% (5.2-20.2) and 0% (0-5.9) at 3 months, 17.6% (11.4-26.4) and 0% (0-25.9) at 6 months, 17.7% (12.6-37.5) and 34.1% (11.4-46.3) at 12 months, 50.0% (25.9-87.5) and 37.5% (25.9-77.4) at 15 months and 50.0% (25.9-87.5) and 66.7% (37.7-100) at 18 months. Factors associated with a higher risk of ADA development were: longer disease duration (1-3 vs. < 1 year; adalimumab: HR 3.0, 95% CI 1.0-8.7; infliximab: HR 2.7, 95% CI 1.1-6.8), moderate disease activity (DAS28 3.2-5.1 vs. < 3.2; adalimumab: HR 6.6, 95% CI 1.3-33.7) and lifetime smoking (infliximab: HR 2.7, 95% CI 1.2-6.3).CONCLUSIONS:The current study focusing on patients co-treated with methotrexate for more than 95% of them found a late occurrence of ADAs not previously observed, whereby the risk continued to increase over 18 months. Disease duration, DAS28 and lifetime smoking are clinical predictors of ADA development

    Mobility, migration, and colonization

    No full text
    Book synopsis: A Companion to the Archaeology of Early Greece and the Mediterranean offers an original and inclusive review of two key periods of Greek archaeology, which are typically treated separately—the Late Bronze Age and the Early Iron Age. It presents an in-depth exploration of the society and material culture of Greece and the Mediterranean, from the 14th to the early 7th centuries BC. The two-volume companion sets Aegean developments within their broader geographic and cultural context, and presents the wide-ranging interactions with the Mediterranean. The companion bridges the gap that typically exists between Prehistoric and Classical Archaeology and examines material culture and social practice across Greece and the Mediterranean. A number of specialists examine the environment and demography, and analyze a range of textual and archaeological evidence to shed light on socio-political and cultural developments. The companion also emphasizes regionalism in the archaeology of early Greece and examines the responses of different regions to major phenomena such as state formation, literacy, migration and colonization

    Crowd-sourcing Hypothesis Tests: Making Transparent How Design Choices Shape Research Results

    No full text
    corecore